Literature DB >> 7994751

IL-10 inhibits alloreactive cytotoxic T lymphocyte generation in vivo.

L Wang1, E Goillot, R I Tepper.   

Abstract

In this report, we present evidence that the CTL response directed against MHC Class I allo-determinants can be inhibited as a result of IL-10 expression in vivo. The presence of localized IL-10 secretion at the site of allogeneic tumor cell challenge resulted in marked inhibition of the CTL response and allowed growth of the tumor in the allogeneic host. Using purified CD4+ T cells from mice immunized in the presence or absence of IL-10, we have shown that the loss of alloreactivity as a consequence of IL-10 expression results from the inhibition of CD4+ T cell function. The expression of either IL-2 or IFN-gamma with IL-10 locally at the time of allogeneic cell challenge completely restored CTL alloreactivity, suggesting that the action of IL-10 could be bypassed by providing helper T lymphocyte-derived cytokines of the Th1 type at the site of immunization. Inhibition of alloreactivity by IL-10 was observed using either purified macrophages or dendritic cells as APC in an in vitro assay. Thus, the expression of IL-10 following antigenic challenge (such as that observed in Th2-like immune responses) may profoundly limit the ability for generating functional CTL in vivo.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7994751     DOI: 10.1006/cimm.1994.1304

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  8 in total

1.  Efficacy of In Vivo Electroporation-Mediated IL-10 Gene Delivery on Survival of Skin Flaps.

Authors:  S Morteza Seyed Jafari; Maziar Shafighi; Helmut Beltraminelli; Benedikt Weber; Ralph A Schmid; Thomas Geiser; Amiq Gazdhar; Robert E Hunger
Journal:  J Membr Biol       Date:  2017-08-03       Impact factor: 1.843

Review 2.  Interleukin-10: a cytokine used by tumors to escape immunosurveillance.

Authors:  F Salazar-Onfray
Journal:  Med Oncol       Date:  1999-07       Impact factor: 3.064

3.  Cytokine/chemokine profile in J774 macrophage cells persistently infected with DA strain of Theiler's murine encephalomyelitis virus (TMEV).

Authors:  Toshiki Himeda; Takako Okuwa; Yasushi Muraki; Yoshiro Ohara
Journal:  J Neurovirol       Date:  2010-05       Impact factor: 2.643

4.  Interleukin-10 promotes B16-melanoma growth by inhibition of macrophage functions and induction of tumour and vascular cell proliferation.

Authors:  M L García-Hernández; R Hernández-Pando; P Gariglio; Jaime Berumen
Journal:  Immunology       Date:  2002-02       Impact factor: 7.397

5.  Role of interleukin-10 in the regulation of tumorigenicity of a T cell lymphoma.

Authors:  Mona R Hassuneh; Mitzi Nagarkatti; Prakash S Nagarkatti
Journal:  Leuk Lymphoma       Date:  2013-01-02

6.  Altered immune responses in interleukin 10 transgenic mice.

Authors:  A Hagenbaugh; S Sharma; S M Dubinett; S H Wei; R Aranda; H Cheroutre; D J Fowell; S Binder; B Tsao; R M Locksley; K W Moore; M Kronenberg
Journal:  J Exp Med       Date:  1997-06-16       Impact factor: 14.307

7.  B7-2 expressed on EL4 lymphoma suppresses antitumor immunity by an interleukin 4-dependent mechanism.

Authors:  C Stremmel; E A Greenfield; E Howard; G J Freeman; V K Kuchroo
Journal:  J Exp Med       Date:  1999-03-15       Impact factor: 14.307

8.  Cytokines required for induction of histocompatibility leukocyte antigen-class I-restricted and tumor-specific cytotoxic T lymphocytes by a SART1-derived peptide.

Authors:  K Matsunaga; M Nakao; K Masuoka; Y Inoue; R Gouhara; T Imaizumi; S Nishizaka; K Itoh
Journal:  Jpn J Cancer Res       Date:  1999-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.